Press releases
-
10/20/2026, Sophia Antipolis, France Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York
Median Technologies and its U.S. subsidiary eyonis Inc. will present eyonis® LCS at this landmark meeting of the international lung cancer screening communityRead more Download 20261020_PR_ielcap_EN_final.pdf -
10/14/2026, Sophia Antipolis, France eyonis Inc., a Median Technologies company, to present study results supporting eyonis® LCS performance claims at CHEST 2026
CHEST 2026 provides an important opportunity to engage with pulmonologists, a key stakeholder group for adoption of AI-enabled decision support solutions in lung cancer screeningRead more Download 20261014_PR_CHEST2026_EN_final.pdf -
10/12/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2026
Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20261012_PR_shares_votingrights_September2026.pdf -
09/15/2026, Sophia Antipolis, France Median Technologies Secures one of the Largest iCRO Projects in its History
The project was awarded by a leading European pharmaceutical company and long-standing Median customer, whose oncology franchise has become its primary growth driver. The contract has a total value of €8.4 million (approximately $9.5 million).Read more Download 20260915_PR_iCROcontract_EN_final.pdf -
09/10/2026, Sophia Antipolis, France H2 2026 Financial Communication Calendar
Median Technologies to release H1 2026 results on October 29, 2026 after market closeRead more Download 20260910_PR_H22026_calendar_EN.pdf -
09/08/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2026
Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260908_PR_shares_votingrights_August2026.pdf -
09/02/2026, Sophia Antipolis, France Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy
Strategic Review to Include Potential Separation of iCRO, Potential U.S. Listing and Other Strategic Alternatives.Read more Download 20260902_PR_SRC_EN_final.pdf -
08/10/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of July 31, 2026
Disclosure of total number of voting rights and number of shares in the capital as of July 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260810_PR_shares_votingrights_July2026.pdf -
07/30/2026, Sophia Antipolis, France Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening
Following FDA 510(k) clearance and CE marking for eyonis® LCS, Median is now focused on accelerating the product’s commercial adoption in the United States and Europe.Read more Download 20260730_PR_CanonOlea_Median_EN_final-1.pdf -
07/22/2026, Sophia Antipolis, France Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications across the eyonis® Portfolio
Median Technologies today announced its key financial performance for the first half of 2026 and highlighted major regulatory and commercial achievements for eyonis® LCS.Read more Download 20260722_PR_H12026keyfigures_EN.pdf